logo

Clinical Trial Results

Share

British drug major AstraZeneca Plc (AZN.L, AZN) announced Monday positive results from the interim analysis of the Phase III ASCEND trial at the European Hematology Association or EHA Annual Congress in Amsterdam. The detailed results demonstrated that Calquence (acalabrutinib) significantly prolonged...

Amgen (AMGN) said Phase 2 BLAST study found that with a median follow-up of 59.8 months, the median OS for BLINCYTO-treated patients was 36.5 months. More than half of patients who achieved a complete MRD response following the first cycle of BLINCYTO treatment were alive at five years. The Phase...

Biotechnology company Regeneron Pharmaceuticals, Inc. (REGN) announced Friday positive early-stage data for REGN1979 in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). The emerging data, which includes patients with R/R diffuse large B-cell lymphoma (DLBCL) who had...

Eli Lilly and Company (LLY) said Taltz demonstrated effectiveness in improving the signs and symptoms of active psoriatic arthritis in a Phase 3b/4 SPIRIT-Head-to-Head study. The trial demonstrated that Taltz was more effective than Humira in simultaneously achieving both joint and skin responses after...

Genentech, affiliated to Swiss drug major Roche Group (RHHBY), announced Thursday that the Phase III PEMPHIX Study with Rituxan (Rituximab) in patients with Pemphigus Vulgaris or PV met the primary and secondary endpoints. The study evaluated the efficacy and safety of Rituxan compared to mycophenolate...

British drug major AstraZeneca Plc (AZN.L, AZN) announced Thursday that the Phase III ELEVATE-TN trial of Calquence (acalabrutinib) met primary endpoint at interim analysis in previously-untreated chronic lymphocytic leukaemia or CLL. In the positive trial, Calquence in combination with obinutuzumab...

Novartis' (NVS) early stage histology data in kidney transplantation suggests that its investigational compound Iscalimab maybe capable of prolonging the durability of transplanted kidneys as well as potentially improving long-term outcomes for kidney transplant patients. The findings are to be confirmed...

pharmaup-jun04.jpg The following are some of today's top gainers in the pharma/biotech sector.

Genentech, a member of the Roche Group (RHHBY), said Tuesday that Phase III study, dubbed BLOCKSTONE, showed Xofluza was effective at preventing influenza infection. The company noted that the late-stage Blockstone study, conducted by Shionogi & Co., met its primary endpoint showing that people exposed...

pharmaup-jun03.jpg The following are some of today's top gainers in the pharma/biotech sector.

Amgen (AMGN) said a Phase 1 study evaluating investigational AMG 510 showed anti-tumor activity when administered as a monotherapy in patients with locally-advanced or metastatic KRASG12C mutant solid tumors. There were no dose-limiting toxicities at tested dose levels. Regarding safety data from the...

pharmaup-may30.jpg The following are some of today's top gainers in the pharma/biotech sector.

pharmaup-may29.jpg The following are some of today's top gainers in the pharma/biotech sector.

pharmaup-may28.jpg The following are some of today's top gainers in the pharma/biotech sector.

pharmaup-may23.jpg The following are some of today's top gainers in the pharma/biotech sector.

Follow RTT